Bulletin from Diamyd Medical’s Extraordinary General Meeting 2026

The EGM approved issuance of up to 24,875,066 warrants, which would increase share capital by up to SEK 2,522,860.285362 if all warrants are exercised. This constitutes the second tranche of the directed issuances announced on March 23, 2026, with subscription rights deviating from shareholders' pre-emptive rights. The move is a routine corporate financing/dilutive action for Diamyd Medical that may modestly affect the share count and equity value upon exercise.

Analysis

The company just introduced a material option overhang via a selective issuance that will act as a latent supply shock on the equity. That overhang changes the marginal supply/demand balance: holders who received the instruments have incentive to hedge or monetize before clinical readouts, increasing share turnover and depressions in implied forward prices in the weeks-to-months window.

Selective allocation implies strategic counterparties rather than a broad retail raise — that skews second-order flows. If recipients are service providers or anchor investors, their behavior differs: CRO/service-provider recipients are less likely to sell immediately (alignment to execution), while financial backers will monetize quickly, accelerating volatility and forcing equity-protecting hedges from existing long holders.

Practically this creates a two-speed catalyst calendar. Near term (days–3 months) expect elevated volatility and downside pressure related to monetization and hedging flows; medium term (3–18 months) the optionality lifecycles (exercise windows, strike economics) determine whether dilution crystallizes or is avoided by partner-funded milestones. The dominant reversal paths are either positive clinical/partnership news that re-rates the stock above exercise-equivalent thresholds or a renegotiation/refinancing that buys out the overhang — absent those, downside via forced supply is the path of least resistance.

Key Decisions for Investors

• Tactical short or underweight Diamyd equity (size 2–4% net portfolio) into near-term volatility. Timeframe 0–3 months; target 20–35% downside if monetization activity accelerates, stop at +15% to limit blow-up on positive readouts. Use borrow or CFDs to avoid dividend/capital structure complications.
• Buy protective puts for existing longs: 6–12 month puts 10–25% OTM sized to cover 50–75% of position. Cost is insurance — treat as portfolio protection through the expected monetization window; breakeven occurs if equity drops ~12–20% depending on premia paid.
• Construct a long-dated capped upside (18–24 month) call-spread to retain upside while funding insurance via selling nearer-term calls. Example structure: buy 24-month ITM/ATM call, sell 12-month OTM call to fund ~60–80% of premium. This preserves upside if clinical/partner catalysts materialize while limiting theta drag.
• Relative-value pair: long a higher-conviction diabetes/autoimmune biotech with comparable stage and cash runway, short Diamyd to isolate idiosyncratic financing/overhang risk. Size pair to be delta-neutral; monitor clinical timelines and partner announcements as pair unwind triggers.